🌍·2d agodiscovery
Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™) Resistant Pancreatic Cancer into a Planned Phase 2 Clinical Trial
Publisher
T
The Manila Times
Global
This page provides publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- The Manila Times
- Region
- Global
- Scope
- discovery
- Published
- September 8, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and related coverage. The publisher did not provide a public summary in this feed. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: The Manila Times
Scope: discovery
Related coverage
More related coverage
Pharmaceutical Technology/4h ago
Podcast: key readouts from ESC and ERS
Pharmaceutical Technology/4h ago
HHS appoints permanent FDA CBER, CDER heads
euractiv.com/4h ago
Spain pushes for ‘access toolbox’ in EU biotech rules
STAT/4h ago